Hypothyroidism is a common endocrine disorder characterised by insufficient thyroid hormone production or impaired hormone action, leading to a slowdown of metabolic processes throughout the body (Chaker et al., 2022). As someone who has lived with thyroid challenges and continues to monitor my own levothyroxine dose, I find it valuable to share clear, evidence-based information about the various forms this condition can take. Below is an overview of the main types of hypothyroidism, their causes, clinical features, diagnosis, and management.
1. Primary Hypothyroidism
Primary hypothyroidism is the most frequent form, accounting for over 95% of cases in iodine-sufficient regions (Jonklaas et al., 2014). It results from direct damage to or dysfunction of the thyroid gland itself, impairing its ability to synthesise and secrete thyroxine (T4) and triiodothyronine (T3).
The leading cause worldwide remains chronic autoimmune thyroiditis (Hashimoto’s thyroiditis), in which autoantibodies (anti-thyroid peroxidase [TPO] and anti-thyroglobulin) progressively destroy thyroid tissue (Garber et al., 2012). Other important aetiologies include:
- Iodine deficiency (still prevalent in parts of Africa, South Asia and some mountainous regions).
- Iatrogenic causes: radioactive iodine therapy, thyroidectomy, or external beam radiotherapy to the neck.
- Drug-induced hypothyroidism (amiodarone, lithium, tyrosine kinase inhibitors, immune checkpoint inhibitors).
- Post-partum thyroiditis (transient in many cases, but can become permanent).
- Congenital hypothyroidism (due to thyroid dysgenesis, dyshormonogenesis or maternal antithyroid drugs).
Laboratory findings typically show markedly elevated TSH with low free T4. Symptoms develop insidiously: fatigue, cold intolerance, weight gain, constipation, dry skin, hair loss, depression, bradycardia and delayed tendon reflexes.
Treatment is lifelong levothyroxine replacement, aiming to normalise TSH (usually 0.4–4.0 mIU/L, though individual targets vary) (Jonklaas et al., 2014). Regular monitoring every 6–12 months is recommended once stable.
2. Central (Secondary and Tertiary) Hypothyroidism
Central hypothyroidism arises from pituitary (secondary) or hypothalamic (tertiary) dysfunction, resulting in inadequate TSH secretion despite low circulating thyroid hormones. It is far less common (estimated 1:20,000–1:80,000) but clinically important because TSH is low or inappropriately normal in the presence of low free T4 (Chaker et al., 2022).
Causes include:
- Pituitary adenomas (most frequent).
- Sheehan’s syndrome (post-partum pituitary necrosis).
- Infiltrative diseases (sarcoidosis, haemochromatosis, Langerhans cell histiocytosis).
- Traumatic brain injury.
- Radiation to the sella turcica.
- Congenital hypopituitarism.
Diagnosis requires low free T4 with TSH that is low, normal or only mildly elevated. Free T3 may also be low. MRI of the pituitary is often indicated. Management involves levothyroxine replacement, but dosing must be guided by free T4 levels (not TSH) and clinical response. Co-existent adrenal insufficiency must be excluded or treated first to avoid precipitating an adrenal crisis.
3. Subclinical Hypothyroidism
Subclinical hypothyroidism is defined biochemically by elevated TSH with normal free T4 and free T3 concentrations. Prevalence increases with age, reaching 10–20% in people over 60 years. Most cases are mild (TSH 4.5–10 mIU/L) (Pearce et al., 2016).
The decision to treat remains controversial and is guided by:
- TSH level (>10 mIU/L is more likely to benefit from treatment).
- Presence of symptoms.
- Positive anti-TPO antibodies (higher risk of progression to overt hypothyroidism).
- Cardiovascular risk factors.
- Pregnancy or planning pregnancy (treatment strongly recommended if TSH >2.5–4.0 mIU/L depending on trimester) (Alexander et al., 2017).
Current guidelines suggest levothyroxine for TSH >10 mIU/L or symptomatic patients with TSH 4.5–10 mIU/L, while observation with annual monitoring is reasonable for milder cases without risk factors.
4. Transient and Drug-Induced Hypothyroidism
Several situations cause temporary thyroid failure:
- Post-partum thyroiditis – biphasic (thyrotoxic then hypothyroid phase), resolves in 80–90% of cases.
- Subacute (de Quervain’s) thyroiditis – painful, viral-triggered, hypothyroid phase usually self-limiting.
- Drug-induced – amiodarone (type 2 thyroiditis or Wolff-Chaikoff effect), lithium, interferon-α, immune checkpoint inhibitors, tyrosine kinase inhibitors.
Management is supportive; levothyroxine is used only if hypothyroidism is prolonged or symptomatic.
5. Congenital Hypothyroidism
Congenital hypothyroidism affects 1 in 2,000–4,000 newborns and is usually due to thyroid dysgenesis (absent or ectopic gland) or dyshormonogenesis. Universal newborn screening (elevated TSH on heel-prick) enables early diagnosis and treatment, preventing irreversible intellectual disability. Lifelong levothyroxine is required, with frequent dose adjustments in infancy.
Clinical and Practical Considerations
Regardless of type, untreated hypothyroidism increases cardiovascular risk (dyslipidaemia, hypertension, heart failure), impairs quality of life and, in severe cases (myxoedema coma), becomes life-threatening. Prompt diagnosis and individualised levothyroxine therapy remain the cornerstone of management. Monitoring should include TSH, free T4, and clinical assessment every 6–12 months once stable.
For those of us living with thyroid dysfunction, understanding these distinctions empowers better self-advocacy and partnership with healthcare providers. Knowledge truly is a form of healing.
References
Chaker, L. et al. (2022) Hypothyroidism. The Lancet, 399(10333), pp. 1536–1552.
